03. Case: Is My Patient Taking His Olanzapine?

Learning Objectives:

After completing this activity, the learner will be able to:

1. The limitations of cross-sectional plasma antipsychotic data to guide treatment decisions
2. The relationship between D2 occupancy and antipsychotic plasma levels
3. How to combine information from antipsychotic plasma levels with the clinical picture to determine an appropriate course of action

Original Release Date: 08/06/2018

Expiration Date: 03/31/2022

Relevant Financial Disclosures: 

The following planners, faculty, and reviewers have the following relevant financial relationships with commercial interests to disclose:

Dr. Meyer has disclosed the following relationships:

• Acadia: Advisory committee, speaking
• Allergan: Advisory committee, speaking
• Alkermes: Advisory committee, speaking
• Intra-Cellular Therapies: Advisory committee
• Janssen Pharmaceutica: Speaking
• Merck: Speaking
• Neurocrine: Advisory committee, speaking
• Otsuka America, Inc.: Speaking
• Sunovion Pharmaceuticals: Speaking
• Acadia: Advisory board, speaking
• Allergan: Advisory board, speaking
• Alkermes: Advisory board, speaking
• Intra-cellular: Advisory board
• Janssen: Speaking
• Impel: Advisory board
• Otsuka: Speaking
• Neurocrine: Advisory board, speaking
• Sunovion: Speaking

All of the relevant financial relationships listed for these individuals have been mitigated.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com